Midkine - Pipeline Review, H1 2020
Midkine - Pipeline Review, H1 2020
SUMMARY
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical stages are 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Gastrointestinal, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Inflammation, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glomerulonephritis, Hypertension, Ischemia Reperfusion Injury, Kidney Disease (Nephropathy), Lung Disease, Neuroblastoma, Osteosarcoma, Prostate Cancer, Solid Tumor and Squamous Non-Small Cell Lung Cancer.
The latest report Midkine - Pipeline Review, H1 2020, outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical stages are 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Gastrointestinal, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Inflammation, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glomerulonephritis, Hypertension, Ischemia Reperfusion Injury, Kidney Disease (Nephropathy), Lung Disease, Neuroblastoma, Osteosarcoma, Prostate Cancer, Solid Tumor and Squamous Non-Small Cell Lung Cancer.
The latest report Midkine - Pipeline Review, H1 2020, outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
- The report reviews Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor projects
- The report assesses Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development
Cellmid Ltd
Ribomic Inc
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iMDK - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Products
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Product Development Milestones
Featured News & Press Releases
Aug 22, 2019: Patent for improved Midkine antibody allowed in Europe
Sep 12, 2018: Cellmid’s lead antibody effective in rare chronic kidney disease
Feb 07, 2017: Cellmid’s European Midkine Patent For Alopecia Allowed
Jan 18, 2017: Cellmid Receives Australian Government Grant For Midkine Programme
Oct 05, 2016: Cellmid’s Midkine Antibodies Show Anti-Tumour Activity against Brain Cancer
Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer
Jun 15, 2015: Cellmid’S Humanised Midkine Antibody Drug Is Safe In Toxicology Studies
Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth
Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development
Cellmid Ltd
Ribomic Inc
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iMDK - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Products
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Product Development Milestones
Featured News & Press Releases
Aug 22, 2019: Patent for improved Midkine antibody allowed in Europe
Sep 12, 2018: Cellmid’s lead antibody effective in rare chronic kidney disease
Feb 07, 2017: Cellmid’s European Midkine Patent For Alopecia Allowed
Jan 18, 2017: Cellmid Receives Australian Government Grant For Midkine Programme
Oct 05, 2016: Cellmid’s Midkine Antibodies Show Anti-Tumour Activity against Brain Cancer
Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer
Jun 15, 2015: Cellmid’S Humanised Midkine Antibody Drug Is Safe In Toxicology Studies
Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth
Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Cellmid Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Dormant Projects, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Cellmid Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Cellmid Ltd
Ribomic Inc
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Cellmid Ltd
Ribomic Inc
